PCWP Analysis

by Cardiosense  · Based in United States → — Cardiac Filling Pressure: At Your Fingertips. Revolutionizing heart failure care with real-time, noninvasive insight into Pulmonary Capillary Wedge Pressure (PCWP), the best predictor of impending crisis.
Cardiology Critical Care Hospital Medicine
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Cardiosense offers an FDA-cleared AI tool, PCWP Analysis Software, designed to noninvasively estimate pulmonary capillary wedge pressure (PCWP) using a wearable sensor called CardioTag™. This technology provides real-time, objective hemodynamic insights to help clinicians more precisely and proactively manage heart failure patients, potentially weeks before fluid buildup and symptoms arise. The solution aims to optimize medical therapy with quantitative, longitudinal hemodynamic history, eliminating guesswork with rapid, easy-to-use, and accurate PCWP readings at the point-of-care, in clinics, or at home. Cardiosense leverages wearable technology, signal processing, and deep learning to convert raw physiological data into clinical intelligence, addressing complex cardiovascular challenges and transforming heart failure management across the patient journey.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Noninvasive PCWP estimation
  • Wearable CardioTagu2122 sensor
  • Real-time hemodynamic insights
  • Objective, quantitative PCWP readings
  • Early detection of worsening heart failure
  • Optimizes medical therapy
  • Point-of-care, in-clinic, and at-home use
  • FDA authorized Class II medical device
  • AI platform for clinical intelligence
  • Reduces heart failure hospitalizations

Use Cases

  • ED assessment and triage for heart failure
  • Inpatient management and discharge optimization
  • Outpatient and at-home PCWP monitoring
  • Optimizing guideline-directed medical therapy (GDMT)
  • Early detection and intervention for heart failure decompensation
  • Reducing heart failure hospitalizations

What Physicians Need to Know

Heart Failure Risk Prediction
The PCWP Analysis Software noninvasively estimates pulmonary capillary wedge pressure (PCWP), a key indicator of fluid buildup that often rises before symptoms appear in heart failure patients. This enables earlier detection of worsening heart failure and proactive management. The technology is currently indicated for adult patients with HFrEF (LVEF u226440%) and NYHA functional class II, III, or IV symptoms. Cardiosense plans to expand its platform with additional algorithms for heart failure detection and management of heart failure with preserved ejection fraction (HFpEF) in the future.
Cardiac Monitoring Integration
The PCWP Analysis Software works in conjunction with the CardioTagu2122 wearable chest sensor. The CardioTagu2122 device, which received FDA 510(k) clearance in July 2025, is the first multimodal wearable sensor to simultaneously capture high-fidelity electrocardiogram (ECG), photoplethysmogram (PPG), and seismocardiogram (SCG) signals. This provides a comprehensive noninvasive view of cardiac function, including electrical activity, blood volume changes, and cardiac mechanical activity. The AI algorithms leverage these signals to estimate hemodynamic parameters.
AHA/ACC Guideline Alignment
The technology was previously published in the Journal of the American College of Cardiology: Heart Failure and presented at the American Heart Association's 2024 Scientific Sessions, demonstrating accuracy comparable to implanted pressure sensors. This aligns with the ongoing efforts to improve heart failure management strategies.
Real-Time Alert Capability
The Cardiosense platform aims to provide timely clinical decision support through early detection and intervention. While not explicitly detailed for PCWP, the general CardioSense AI platform offers real-time alerts for critical cardiac conditions, prioritizing findings based on clinical urgency and allowing configurable notifications to healthcare providers.
Physician Tip

The Cardiosense PCWP Analysis Software offers a noninvasive method to estimate PCWP, traditionally requiring invasive procedures. This can facilitate more frequent and proactive hemodynamic monitoring in eligible HFrEF patients (LVEF u226440%, NYHA Class II-IV symptoms) in various settings, including at the bedside, in clinic, or at home. The rapid availability of quantitative PCWP readings (in minutes) can aid in optimizing medical therapy and potentially preventing hospitalizations by allowing for earlier intervention before symptomatic decompensation. While promising for guiding individualized therapy adjustments, it's important to note that current authorization is specific to HFrEF, and outcome data demonstrating reduced hospitalization or improved quality of life are not yet available.

The PCWP Analysis Software integrates with the CardioTagu2122 wearable chest sensor. The broader CardioSense AI platform supports seamless integration with existing Electronic Medical Record (EMR) systems, including Epic, Cerner, and Allscripts, through HL7 FHIR standards and custom API endpoints. This suggests a potential for future integration of PCWP data into comprehensive patient records and workflows.

Details

Category Cardiology AI, Clinical Decision Support & Reference, Wearables & Remote Monitoring (RPM)
Pricing Contact for pricing
DeploymentCloud-based software with wearable sensor
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The CardioTag™ device and PCWP Analysis Software™ have been authorized to market as class II medical devices in the US via De Novo classification. They are FDA authorized and validated against right heart catheterization with accuracy on par with implantable sensors.
Integrations
EHR Not specified
Specialties Cardiology, Critical Care, Hospital Medicine

What the Web Says

Cardiosense's PCWP Analysis Software, used with the CardioTag wearable sensor, offers a noninvasive method to estimate pulmonary capillary wedge pressure (PCWP), a key indicator of fluid buildup in heart failure patients. This technology aims to provide earlier detection and more proactive management of heart failure, potentially reducing hospitalizations. The software recently received FDA De Novo classification, establishing a new regulatory category for this AI-based, noninvasive PCWP estimation.

Overall: Positive

Strengths

  • Noninvasive measurement of PCWP, traditionally requiring invasive catheterization or implants.
  • Enables earlier detection of worsening heart failure and proactive management.
  • Accuracy comparable to implanted pressure sensors.
  • Potential to reduce hospitalizations and improve quality of life for heart failure patients.
  • Rapid quantitative PCWP readings available in minutes.
  • Easy-to-use CardioTag sensor deployable at point-of-care, bedside, clinic, or home.

Limitations

  • No specific cons were found in the provided search results from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra regarding the PCWP Analysis Software itself. The Reddit discussions focused on general PCWP interpretation rather than reviews of this specific product.
  • Limited independent user reviews from platforms like G2 or Capterra were found, likely due to the recent FDA authorization and specialized nature of the medical device.
  • The CardioSense app (a different product) has limited ratings (1 rating, 5.0 out of 5) on the Apple App Store, which is not directly relevant to the PCWP Analysis Software.

Based on reviews from: Cardiovascular Business, Medical Product Outsourcing, Becker's ASC Review, Medical Economics, HCPLive, Business Wire, Journal of the American College of Cardiology: Heart Failure, PubMed, Cardiosense.com, The Journal of Innovations in Cardiac Rhythm Management, Startup Intros

Last updated: 2026-07-01

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate PCWP Analysis

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

OEM News
Cardiosense Wins FDA De Novo Nod for PCWP Analysis Software
Cardiosense has received FDA de novo classification for its PCWP Analysis Software, an AI-powered technology that noninvasively estimates pulmonary capillary wedge pressure (PCWP) using a chest sensor, aiming to improve heart failure management. This marks a significant step in providing earlier detection and more proactive treatment for heart failure patients.
2026-05
Medical Economics
Cardiosense receives FDA authorization for heart failure monitoring software
Cardiosense announced FDA De Novo classification for its AI-based PCWP Analysis Software, which noninvasively estimates pulmonary capillary wedge pressure to detect fluid buildup in heart failure patients before symptoms appear. This technology, used with a wearable chest sensor, aims to enable earlier intervention and better treatment management.
2026-05
HCPLive
FDA Grants De Novo Status to Cardiosense PCWP Software for HFrEF - HCPLive
The FDA has granted de novo classification to Cardiosense's PCWP Analysis Software, an AI-enabled tool for noninvasive estimation of pulmonary capillary wedge pressure in adult heart failure patients with reduced ejection fraction (HFrEF). This software, used with a wearable sensor, provides a noninvasive alternative to traditional invasive methods for assessing cardiac congestion.
2026-05
Cardiovascular Business
FDA gives greenlight to new AI tool for managing heart failure patients - Cardiovascular Business
The FDA has approved Cardiosense's PCWP Analysis Software, an AI-powered tool that noninvasively estimates pulmonary capillary wedge pressure (PCWP) using a wearable sensor, offering a novel approach to managing heart failure. This de novo classification allows for the first-of-its-kind technology to track fluid buildup in heart failure patients without invasive procedures.
2026-05
Business Wire
Cardiosense Receives FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure - Business Wire
Cardiosense announced that the FDA has granted De Novo classification for its PCWP Analysis Software, a first-in-class noninvasive technology to estimate pulmonary capillary wedge pressure (PCWP). This AI-powered software, used with a wearable sensor, aims to provide clinicians with critical data for improved heart failure therapy and to prevent hospitalizations.
2026-05
accessdata.fda.gov
Software device system for estim - accessdata.fda.gov
The FDA has classified Cardiosense's PCWP Analysis Software as a Class II prescription device, intended to noninvasively estimate pulmonary capillary wedge pressure (PCWP) and identify patients with PCWP above or below 18mmHg. This software is for adult heart failure patients with reduced ejection fraction and NYHA Functional Class II, III, IV symptoms, to be used in conjunction with other standard care parameters.
2026-05
American Healthcare & Hospital Management
Cardiosense Secures FDA De Novo Clearance for Heart Failure Monitor
Cardiosense has received FDA De Novo classification for its PCWP Analysis Software, a new technology that non-invasively assesses pulmonary capillary wedge pressure (PCWP) in heart failure patients using AI and a wearable chest sensor. This aims to help clinicians identify early signs of worsening heart failure and adjust treatment to potentially reduce hospital admissions.
2026-05
BioSpace
Cardiosense Receives FDA 510(k) Clearance for the CardioTagu2122 Device, Paving the Way for Advanced Cardiac Function Monitoring - BioSpace
Cardiosense received FDA 510(k) clearance for its CardioTag device, a multimodal wearable sensor that captures various cardiac signals, laying the groundwork for advanced cardiac AI platforms. The company's PCWP algorithm, which has FDA Breakthrough Device designation, demonstrated accuracy comparable to implantable sensors and will be paired with CardioTag upon regulatory approval for the PCWP Analysis Software.
2025-07

Videos

Product demos, reviews, and walkthroughs for PCWP Analysis.

View all on YouTube

Frequently Asked Questions

AI-powered PCWP analysis aims to provide rapid and potentially more consistent interpretations of pressure waveforms compared to manual analysis, which can be subject to inter-observer variability. While still evolving, the goal is to enhance diagnostic speed and accuracy, particularly in critical care settings where timely decisions are crucial.
The use of AI in PCWP analysis falls under medical device regulations, requiring rigorous validation, clinical trials, and regulatory approvals (e.g., FDA in the US, CE Mark in Europe) to ensure safety and efficacy. Compliance with data privacy laws like HIPAA is also paramount, as patient data is utilized and processed by these AI systems.
Traditional manual interpretation by experienced cardiologists and intensivists remains the established alternative, often considered the gold standard. These methods might be preferred in complex cases with atypical waveforms or when AI algorithms have not been sufficiently validated for specific patient populations or clinical scenarios.
Pricing models for AI-driven PCWP analysis can vary, ranging from subscription-based services per use or per patient, to one-time licensing fees for software integration. These costs can impact hospital budgets, requiring careful evaluation of the return on investment in terms of improved patient outcomes, reduced length of stay, and optimized resource utilization.
Current limitations of AI in PCWP analysis include potential difficulties with noisy or artifact-laden signals, challenges in interpreting highly unusual waveform morphologies, and a lack of generalizability across diverse patient populations. Physician oversight remains crucial for contextualizing AI outputs with the patient's overall clinical picture, managing unexpected findings, and making final diagnostic and treatment decisions.
Seamless integration with existing EHR systems is a key concern for AI-powered PCWP analysis to ensure efficient data flow and avoid workflow disruptions. Solutions often aim to provide results directly within the EHR, allowing for easy access by clinicians and facilitating comprehensive patient management.
AI models for PCWP analysis are typically trained on large datasets of annotated pressure waveforms, often collected from diverse patient populations and clinical settings. The robustness of these models depends on the quality, size, and diversity of the training data, as well as rigorous validation against independent datasets and real-world clinical scenarios.

Related Tools

Cardiomatics
Cardiomatics
Cardiology AI
Cardiomatics is a cloud-based, AI-powered software for analyzing ambulatory (Holter) ECG tests, using clinically validated algorithms to provide accurate and high-quality results for cardiac diagnostics. It aims to streamline ECG analysis, reduce interpretation time, and improve diagnostic accuracy for various heart conditions.
Paid, credit-based or subscription
SafeBeat Rx App
SafeBeat Rx, Inc.
Cardiology AI
An AI application designed to support safe pharmacological treatment and monitoring for cardiac arrhythmias.
PreemptiveAI Clinical SDK
Measure Labs, Inc. (Dba Preemptiveai, Inc.)
Cardiology AI
A clinical software development kit using AI to model and predict cardiovascular health metrics, aiming to shift healthcare from reactive to proactive by providing early health risk signals.
Clarius Ejection Fraction AI
Clarius Mobile Health Corp.
Cardiology AI
Clarius Ejection Fraction AI is an AI-powered ultrasound tool for automated left ventricular ejection fraction calculation, integrated into the Clarius Ultrasound App for real-time cardiac assessments.
Contact for pricing
Automated Aortic Stenosis Software (AutoAS)
Multiple companies are developing Automated Aortic Stenosis Software (AutoAS) or similar AI-powered solutions. Notable ones include iCardio.ai, Us2.ai, AccurKardia, HeartSciences Inc., and Echo IQ.
Cardiology AI
Automated Aortic Stenosis Software (AutoAS) is an ultrasound application by GE Medical Systems that provides automated assessment of aortic stenosis to enhance diagnostic efficiency and consistency.
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm
Anumana
Cardiology AI
An AI algorithm that analyzes standard 12-lead ECG recordings to detect signs of pulmonary hypertension, aiming for earlier diagnosis and improved patient outcomes.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-07-01 | First Added: 2026-07-01

Investors who backed PCWP Analysis

Funded through the company that built this tool.
OSF HealthCare Ventures
Corporate VC T3
Peoria, United States
$1M-$5M
OSF HealthCare Ventures is the corporate investment arm of OSF HealthCare, a multi-state Catholic non-profit health system based in the US Midwest.…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
AI Tool Finder
AI-powered search. Results may not be comprehensive.